论文部分内容阅读
《JAMA》1984;251(13):1651. 美国巴尔的摩、波士顿和圣路易斯的研究人员希望本月完成用遗传工程生产的人蛋白溶解冠状动脉和其它血管中血凝块的临床试验。这种物质命名为组织型纤维蛋白溶酶原激活剂,或t-PA与其它纤维蛋白溶酶原激活剂如链激酶或尿激酶不同,t-PA在体内只有少量,只作用于血中的凝块而对其它蛋白无作用。加利福尼亚南旧金山的基因技术公司正在生产此制剂。巴尔的摩的城市医院和约翰斯·霍布金斯医院等进行的研究性试验包括45名病人。此项试验是在食品和药物管理局批准后进行的。
JAMA 1984; 251 (13): 1651. Researchers in Baltimore, Wash. And St. Louis, USA, hope to complete clinical trials of genetically engineered human proteins to dissolve blood clots in the coronary arteries and other blood vessels this month. This material is named tissue-type plasminogen activator, or t-PA and other plasminogen activators such as streptokinase or urokinase, t-PA in the body only a small amount, only in the blood Clot and no effect on other proteins. GeneChip Inc., of South San Francisco, California, is producing the drug. The research trial conducted at Baltimore’s City Hospital and Johns Hopkins Hospital included 45 patients. This trial was conducted with the approval of the Food and Drug Administration.